Are you aware of the biggest bear trap of patient-facing pricing research?
Read our white paper to explore this bear trap and how econometric modeling could save your pricing strategy.
Read MoreAll Inpharmation’s pricing, forecasting, and demand market research solutions are based on years of development, calibration, and research.
Below you can browse a selection of interesting white papers. Many of these papers provide head-to-head validation and evidence as to why Inpharmation’s solutions are best placed to provide you with the most reliable insights.
To receive a full free copy of any white paper:
Read our white paper to explore this bear trap and how econometric modeling could save your pricing strategy.
Read MoreCreating an uptake forecast for a first-in-class product is fraught with uncertainty. So far in this series of papers on uptake, we have covered how the Bass uptake model distils prescriber behavior into two coefficients: innovation (p) and imitation (q). For a me-too brand, it is simple to determine the values of these two coefficients […]
Read MoreForecasting the uptake of competing products is complex and requires substantial Excel skills. The previously covered Bass model is great for forecasting individual product uptake, but what about when you need to forecast the uptake of your product amongst competition? It isn’t as simple as forecasting the uptake of each competitor individually – you need […]
Read MoreCreating a forecast for a new pharmaceutical is daunting but exciting. The forecast is likely to be driven by just a few key assumptions: the treatable patient population, the peak market shares of competing products, and how quickly products achieve these peak market shares — their uptake rate. Getting these assumptions “right” is paramount to […]
Read MoreOncology forecasting has become significantly more complex for two main reasons: First, the knock-on effects of improving efficacy (which we call the tsunami effect). Second, the increasing control that regulators and payers are exercising over which lines of therapy products can be used in (which we call the “shadows and lights” effect). In this article, […]
Read MoreForecasters are often critical of “black box” forecasts. When a forecaster cannot trace the numbers from input to output using simple math, the forecast is deemed an untrustworthy “black box”. On the face of it, this criticism seems fair. However, the evidence shows that using well-validated forecasting algorithms—rather than relying on human judgment—produces more accurate […]
Read MoreUsing products similar to your own to forecast the performance of your product is popular and, on the face of it, intuitive. Unfortunately, analogues often produce terrible forecasts. This article explains the two analogue traps and explores how you can generate more useful forecasts.
Read MoreAt Inpharmation, we developed the Pharma-Specific Conjoint platform specifically to address the challenges of reliability and sample size in pharma market research. We transform preference shares into more accurate market shares before finally incorporating the additional jigsaw pieces to generate pharma-validated, forecast-ready market shares. This series of papers will show you the key steps to […]
Read MoreThe speed and uptake of first-in-class products is highly variable. However, it is hard to find analogous products to base your forecast on. This article explains how three drivers impact the shape of uptake curves.
Read MoreSpeaking to just a handful of payers risks your price strategy suffering from unreliable wide-ranging price responses. Price strategies rely on quantitative metrics, and quantitative metrics must be powered with reliable respondent sample sizes. However, payers can be difficult to recruit into research projects, especially outside of the US. This article investigates what constitutes a […]
Read MoreArtificial intelligence is having a profound effect in pharma R&D. For example, it is making wonderfully accurate predictions of protein folding. Why is it not having a similarly revolutionary impact on demand and price forecasting? This article explains why.
Read MoreMany payers do not use QALYs when making pricing decisions. Nevertheless, they behave as if they do. This article explains why the best predictive models often do not reflect reality. We use, as an example, the usefulness of QALYs in predicting payer decisions.
Read MoreThe Institute for Clinical and Economic Review (ICER) is a US lobby group that looks at the clinical benefit of value-added drugs and recommends “cost-effective” prices. Their definition of cost-effectiveness is not a hard barrier, such as the one used by NICE in the UK, but is a range of thresholds, the highest of which […]
Read MoreMany forecasts are guided by so-called “patient allocation” exercises. Here, prescribers are asked to predict how many of their patients they would treat with each current product and (usually) one novel product—whose profile they are shown. This seems a sensible approach. However, you must distinguish between research questions (what you want to know) and survey […]
Read MoreMulti-criteria decision analysis (MCDA) is occasionally used as a tool to predict the price opportunity of new pharmaceuticals. This white paper explains the advantages and disadvantages of the approach.
Read MoreConjoint studies frequently assume that product profile is the dominant driver of market share. However, product profile is often not the dominant driver and rarely is it the sole driver of market share. Other factors affect market share too, and you need to combine them with the output from your conjoint. In this final paper […]
Read MoreSo far in this series of papers on making conjoint fit for pharma, we have explored how you can increase the reliability of responses and decrease the required sample size of your pharma conjoint studies to produce preference shares. However, market research agencies often advise that the preference shares that come out of conjoint studies […]
Read MoreIn the previous paper of this series “Making conjoint fit for pharma”, we discussed why traditional conjoint approaches overburden respondents in pharma market research. In this paper, we explore the impact of sample size on reliability, the challenges of recruiting enough respondents to drown out the noise, and how a fit-for-pharma conjoint platform solves these […]
Read MoreConjoint is a wonderful idea for demand market research. By asking a sample of respondents a series of questions, you get an “X-ray” into their minds. You learn which product attributes are important to them and which are not. You can quantify how different product performance levels contribute to preference and market share. Conjoint is […]
Read More